DALLAS and NEW YORK, May 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that it had made significant progress with the commercial introduction of MuGard in the radiation oncology and medical oncology communities. MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating that has been shown to be very effective in the management of oral mucositis, a debilitating side effect of many anticancer treatments. Access provided the following information related to its ongoing commercialization efforts:
Access continues to collect clinical data and anecdotal feedback from clinicians, nurses and patients across the US. Recent testimonials, all of which will be included in the testimonial page of www.MuGard.com, include the following: "...Mucositis is a debilitating condition and there is a strong need to find a treatment…our experience with MuGard has been that it provides tremendous relief to our oral mucositis patients, and we will continue to recommend it and prescribe it our patients."-Sawsan Bishay M.D., Larry Gandle, M.D., and Arthur Markowitz, M.D.Florida Cancer Institute – New Hope"...We are currently recommending MuGard to all of our head and neck patients." -Steven Lane, M.D. and Sarah Usher RN MSN OCNSignature Healthcare Brockton Hospital Vantage Oncology - Brockton, MA"...Mucositis has been an expected side effect that causes our patients significant pain and even treatment delays at times. MuGard is the best product I've seen at preventing oral mucositis … Patients find it very convenient that MuGard is ready to use without mixing and safe to swallow … We look forward to using MuGard for our future head and neck cancer patients."-Bonnie Arritola, RN, BSN, OCNHealth ONE Hospital – Denver, CO"Access is extremely pleased with the initial progress of the commercial roll-out of MuGard," stated Jeffrey B. Davis, President and CEO, Access Pharmaceuticals. "Clinical feedback has been extremely positive, and we as a Company remain committed to getting this very important treatment option to doctors, nurses and patients. Oral mucositis, while not widely understood by the investing public, is a very large and growing healthcare unmet clinical need; MuGard meets that need."
"The MuGard prescription ramp is exceeding my expectations," said Frank Jacobucci, Vice President of Sales and Marketing for Access Pharmaceuticals. "Access continues to identify and train additional MuGard representatives to further expand our footprint in the US, and believes this will add significantly to current prescription growth, clinical experience and general MuGard awareness."
"The very positive clinical feedback and commercial uptake of MuGard had a significant impact on my decision to join Access Pharmaceuticals," stated Anthony Mottola, Vice President, Managed Care and Market Access. "I am spearheading internal efforts to expand third party payor outreach, enhance our nationwide distribution capabilities, and add certain components to our offering such as hotline services and additional hub and distribution capabilities. We will announce additional collaborations in this area as they occur."
Investor Conference Call Details:An investor conference call is scheduled to be held on Tuesday, May 24, 2011 at 11:00 am EDT. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. A replay of the call will be available starting on May 24, 2011 at 1:00 pm EDT, through June 07, 2011 until 11:59 pm EDT. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 372986.
About MuGard:MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, please visit www.MuGard.com.
About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Investor RelationsChristine Berni
Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations
Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.
(212) 370-4500(212) 786-6208
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved